NASDAQ: MNPR Monopar Therapeutics 8-K

Monopar presents Phase 2 Wilson disease trial results at major European liver conference

Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read

3 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade MNPR commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 4:05 AM